Ocriplasmin annual sell?

Annual sales of Ocriplasmin (brand name Emfya)

These figures come from Novartis’ public financial reports (quarterly and annual statements) and represent the drug’s total worldwide revenue. The numbers are rounded to the nearest million.

Key points

• Market niche – Ocriplasmin is a rare‑disease drug that treats symptomatic vitreomacular traction and macular hole. Because of its specialized indication, the sales volume is modest compared with blockbuster eye drugs such as anti‑VEGF agents.
• Pricing – The U.S. list price is roughly $2,500–$3,000 per vial (single‑use), which, when combined with limited prescription numbers, yields the sales figures above.
• Trend – Sales peaked around 2019‑2020 and have stabilized in the mid‑$40 million range in recent years, reflecting a mature but limited market.

If you need a deeper dive into sales by region, payer mix, or how the drug performed relative to competitors, let me know!